

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of December, 2024

Commission File No. 001-39621

---

**OPTHEA LIMITED**  
(Translation of registrant's name into English)

---

Level 4  
650 Chapel Street  
South Yarra, Victoria, 3141  
Australia  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

---

---

EXHIBIT INDEX

---

Exhibit	Description
99.1	<a href="#">Press Release - Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**OPTHEA LIMITED**

(Registrant)

By: /s/ Frederic Guerard

Name: Frederic Guerard

Title: Chief Executive Officer

Date: 12/19/2024

---

**ASX, Nasdaq and Media Release**

December 19, 2024

**Opthea to Present at 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference***Business update to include masked Phase 3 patient demographics and baseline characteristics**Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California*

**Melbourne, Australia, and Princeton, NJ, US, December 19, 2024** -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT.

Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea's executive team will attend the conference and be available for one-on-one meetings January 13-16, 2025.

The live webcast and presentation will be accessible on the "Events & Presentations" section of the Company's website at <http://ir.opthea.com/>, where the replay will be available for 30 days.

**About Opthea**

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](#), and ShORe, [NCT04757610](#)) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at [www.opthea.com](http://www.opthea.com) and follow us on [X](#) and [LinkedIn](#).

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

---



### **Investor Inquiries**

PJ Kelleher  
LifeSci Advisors LLC  
Email: [pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)  
Phone: 617-430 7579

### **Media Inquiries**

Silvana Guerri-Lena  
NorthStream Global Partners  
Email: [silvana@nsgpllc.com](mailto:silvana@nsgpllc.com)

***Join our email database to receive program updates:***

Tel: +61 (0) 3 9826 0399  
Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

**Source: Opthea Limited**

---

